LiDCO : US purchasing agreement with group of 38 US hospitals

13 October 2015

LiDCO (AIM:LID), the hemodynamic monitoring Company, announces that following an extensive competitive evaluation for non-invasive hemodynamic monitoring it has been awarded a five year purchasing agreement by MedAssets, a US based group purchasing organisation.

MedAssets is a leading healthcare performance improvement company that serves four out of five hospitals in the USA, and have awarded the purchasing agreement on behalf of a large US healthcare group. The major healthcare group serves 10 million people each year in 38 hospitals across eight US states.

Commenting Matt Sassone, Chief Executive Officer, said:
'This purchasing agreement is a very exciting opportunity for LiDCO and has the potential to substantially enhance our business in the USA as it opens up sales into 38 new US hospitals. Whilst the agreement is expected to have a minimal impact on this year's numbers we are confident that it will provide a platform for greater growth in the midterm, with larger opportunities being realised in the next financial year.'

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

• early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
• quantification of hemodynamic response
• guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid^v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BIS^TM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

*BIS^TM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

**CNAP^TM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.

Back to News Releases